Aditi Jain, Ph.D.
Affiliations: | 2013 | Idaho State University, Pocatello, ID, United States |
Area:
Pharmacy, Biomedical Engineering, OncologyGoogle:
"Aditi Jain"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Alok Bhushan | grad student | 2013 | Idaho State University | |
| (Potential treatment strategies for glioblastoma multiforme: Role of biochanin A, a dietary isoflavone in inhibiting angiogenesis and in modulating anticancer effects of temozolomide on brain tumor progression, invasion and DNA damage response pathways.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Verma P, Rishi B, George NG, et al. (2023) Recent advances and future directions in etiopathogenesis and mechanisms of reactive oxygen species in cancer treatment. Pathology Oncology Research : Por. 29: 1611415 |
| McCarthy GA, Di Niro R, Finan JM, et al. (2023) Deletion of the mRNA stability factor (HuR) in pancreatic cancer cells disrupts the tumor microenvironment integrity. Nar Cancer. 5: zcad016 |
| McCarthy GA, Jain A, Di Niro R, et al. (2023) A Novel 3DNA® Nanocarrier effectively delivers payloads to pancreatic tumors. Translational Oncology. 32: 101662 |
| Bhardwaj V, He J, Jain A. (2022) Glutamine stabilizes myc via alpha-ketoglutarate and regulates paclitaxel sensitivity. Medical Oncology (Northwood, London, England). 39: 227 |
| Jain A, McCoy M, Coats C, et al. (2022) HuR Plays a Role in Double-Strand Break Repair in Pancreatic Cancer Cells and Regulates Functional BRCA1-Associated-Ring-Domain-1(BARD1) Isoforms. Cancers. 14 |
| Jain A, Bhardwaj V. (2021) Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities. World Journal of Gastroenterology. 27: 6527-6550 |
| Schultz CW, McCarthy GA, Nerwal T, et al. (2021) The FDA approved anthelmintic Pyrvinium Pamoate inhibits pancreatic cancer cells in nutrient depleted conditions by targeting the mitochondria. Molecular Cancer Therapeutics |
| Agostini LC, Jain A, Shupp A, et al. (2020) Combined targeting of PARG and Wee1 causes decreased cell survival and DNA damage in an S-phase dependent manner. Molecular Cancer Research : McR |
| Dhir T, Schultz CW, Jain A, et al. (2019) Abemaciclib is effective against pancreatic cancer cells and synergizes with HuR and YAP1 inhibition. Molecular Cancer Research : McR |
| Jain A, Agostini LC, McCarthy GA, et al. (2019) Poly (ADP) ribose glycohydrolase can be effectively targeted in pancreatic cancer. Cancer Research |